The Alphabet company will maintain the use of third-party cookies for those who do not disable them, marking a significant shift from Google’s previous strategy, but still aimed at the end goal of improving user privacy while preserving advertising effectiveness.
With promising Phase II data in hand, Viking Therapeutics is pushing its subcutaneous GLP-1/GIP receptor dual agonist into late-stage development, the company announced.
Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.
Overall, the company’s quarterly sales came in at $14.46 billion, beating estimates of $14.03 billion. On an adjusted basis, AbbVie earned $2.65 per share, beating estimates by 8 cents.
AstraZeneca beat analyst expectations for its second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines.
ReutersRoche raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as eye medicine Vabysmo.